What Synbiotech does

Synbiotech (legal name 生合生物科技股份有限公司, Synbio Tech Inc.; TPEx stock code 1295) is a Taiwan-headquartered developer and manufacturer of probiotic and postbiotic functional ingredients, founded in 2000 in Kaohsiung and operating globally with subsidiaries in Yangzhou, China. The company serves B2B nutraceutical, functional food, sports nutrition, animal health and dietary supplement brand owners across more than 30 countries, supplying clinically validated proprietary strains such as TWK10® (sports/muscle), FS4722™ (uric acid via gut-liver-kidney axis), SYNMUE™/LP28 (immunosenescence), LDL557™ (gut-joint axis), SynForU® HerCare (vaginal/intimate wellness), SynForU® ReMain (kidney), SynForU®-GastroKeep (stomach), ABKefir® (gut), BY2 (cholesterol), and M1 (respiratory), alongside pet/animal/aquaculture/silage probiotics (SYNPET®, SYNLAC®, 水益旺®, 芯發旺®). Underpinning the portfolio are two technology platforms: SYNTEK® thorough, an integrated strain selection, fermentation, functional strengthening and freeze-drying manufacturing process recognized by Frost & Sullivan as one of four innovative global probiotic manufacturing processes, and SYNPACK™ packaging technology, which guarantees viable bacteria count over a 24-month shelf life using 68 monitoring points plus dynamic gas control. The company also operates a proprietary lactic acid bacteria strain bank established in 2000, a dedicated Microbiome and Lactic Acid Bacteria Application R&D Center established in 2018, and 60+ patents across human and animal probiotic applications.

The business model is multi-revenue-stream and B2B-led: (1) ingredient sales of proprietary probiotic and postbiotic strains under multi-year B2B contracts at negotiated volume-based pricing; (2) CDMO/OEM/ODM custom formulation, blending and packaging services across the full product lifecycle; (3) global brand licensing and royalties through exclusive distribution partnerships—most notably Lonza for TWK10 in the US, Canada, Europe and Brazil and Cosmax NBT for Korea; and (4) branded consumer products in Taiwan (including the SYNPET® pet range and 庫米思® concentrated probiotic beverages). GTM combines enterprise field sales, recurring presence at international trade shows (Vitafoods Europe/Asia, Probiota Americas, ACLAB) as customer-acquisition venues, and content marketing through the ProbioticHub (BiomeHub/TrendSphere) plus social/earned media across LinkedIn, Facebook, YouTube, Instagram, X and WeChat. Financials: FY2023 revenue TWD 823M with TWD 113M after-tax net profit and EPS TWD 3.67; 9M 2024 revenue TWD 743M and net profit TWD 148M (EPS TWD 4.71), already exceeding the full-year 2023 profit, with profitability accelerating ahead of the Q2 2025 commissioning of a new NT$1.9B Kaohsiung factory that will increase production capacity fivefold.

Name

Synbiotech

Legal name

生合生物科技股份有限公司

Website

https://synbiotech.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Synbiotech is a Taiwan-based probiotic and postbiotic ingredient developer (TPEx: 1295), founded 2000. It supplies clinically validated strains such as TWK10 to B2B nutraceutical, functional food, sports nutrition, and animal health brands across 30+ countries.

Ownership category

akta.pro rank

Product category

Probiotic and Postbiotic Ingredients

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Food Manufacturing (311)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Probiotics (Strains, Spore-Formers, Synbiotic Components) (AFAJAKAE)

akta.pro secondary industries

Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases) (AFAJAJAE), Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials) (AFADALAE), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI), Probiotic/Direct-Fed Microbial (DFM) Premixes (AFADAGAG)

Keywords

• Probiotic ingredients
• Postbiotic manufacturing
• Lactic acid bacteria
• CDMO services
• Functional probiotic strains

Headquarters

HQ city

Kaohsiung

HQ country

Taiwan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Probiotic Ingredient B2B Sales: Sale of proprietary probiotic strains (TWK10, FS4722, ABKefir, SynForU series, LDL557) and postbiotic ingredients to global nutraceutical, functional food, sports nutrition, and dietary supplement brands. Ingredients are supplied as powder to manufacturers.
2. CDMO / OEM / ODM Manufacturing Services: Contract development and manufacturing organization providing customized probiotic formulations, blending, and packaging services for brand partners. Covers the full product lifecycle from strain selection and clinical validation to customized formulations and smart packaging. One-stop service model.
3. Global Brand Licensing: Licensing of proprietary strains and brand rights to international partners (e.g., Lonza for US/EU, Cosmax NBT for Korea). Generates royalties and market授权 fees through exclusive distribution agreements and brand partnerships.
4. Branded Consumer Probiotic Products: Direct-to-consumer and brand product sales including dietary supplement products for sports nutrition, healthy aging, and pet health (SYNPET line). Consumer products are sold in Taiwan market through retail channels.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

Core offering

Synbiotech develops, manufactures, and supplies proprietary probiotic and postbiotic ingredients — branded strains such as TWK10 (sports/muscle), SYNMUE (immune aging), FS4722 (uric acid), the SynForU series (women's health, kidney, stomach), ABKefir, LDL557, BY2, M1, and SYNPET — to global nutraceutical, functional food, sports nutrition, dietary supplement, and pet/animal health brand owners. The company also operates a CDMO/OEM/ODM service providing customized probiotic formulations, blending, and packaging, and licenses proprietary strains and brands to international partners.

Product overview

Synbiotech is a Taiwan-based developer and manufacturer of probiotic and postbiotic ingredients, offering a portfolio of branded functional probiotic strains, proprietary manufacturing technologies, and packaging solutions. Core products include TWK10® (flagship sports/aging probiotic), SYNMUE™ (LP28 for immune aging), FS4722™ (uric acid management), and SynForU® functional series (HerCare for women's health, ReMain for kidney health, GastroKeep for stomach health). The company provides ABKefir® (kefir-based gut health), LDL557™ (postbiotic for joints), BY2 (cholesterol support), and M1 postbiotic (respiratory health). SYNPET® covers pet probiotics. Technology platforms include SYNTEK™ thorough (optimized fermentation manufacturing) and SYNPACK™ (guaranteed viability packaging). Products serve sports nutrition, healthy aging, women's health, digestive health, joint mobility, metabolic health, and pet wellness segments.

Differentiator

Problem solved

Functional benefit

Brands

• TWK10®: Flagship probiotic strain (Lactiplantibacillus plantarum TWK10®) targeting sports nutrition, muscle health, and healthy aging; won multiple international awards including NutraIngredients Europe Awards 2026 (Ingredient of the Year: Sports Nutrition), USA, and Asia awards.
• SynForU™
• ABKefir®
• LDL557™
• FS4722™
• SYNTEK®
• SYNPACK™
• SYNPET®
• 芯來旺® (SYNLAC)
• 水益旺®
• 芯發旺®
• 庫米思® (Kumis)

Products and services

• TWK10® Flagship probiotic strain (Lactiplantibacillus plantarum TWK10) sourced from Taiwanese fermented vegetables, supporting muscle health, sports performance, and healthy aging through the gut-muscle axis mechanism; available in both live probiotic and heat-killed postbiotic formats. Used as an ingredient in sports supplements, protein drinks, and functional foods.
• SYNMUE™ Clinically validated probiotic featuring Lactiplantibacillus plantarum LP28, designed to target immunosenescence (immune aging) and support immune resilience in older adults; positioned in the healthy aging market.
• FS4722™ Probiotic strain (Lactiplantibacillus plantarum FS4722) isolated from traditional Chinese pickled vegetables, targeting hyperuricemia and uric acid metabolism through the gut-liver-kidney axis.
• SynForU® HerCare Six-strain probiotic complex targeting women's intimate wellness and microbial balance, supporting daily feminine health maintenance, with clinical trial collaboration in pregnant women.
• SynForU® ReMain Dual-strain probiotic combination focused on the gut-kidney axis and metabolic balance for kidney health support.
• SynForU™-GastroKeep (LP23) Multi-strain probiotic complex featuring Lactobacillus plantarum LP23 for stomach health, with acid and bile salt resistance properties.
• LDL557™ Heat-inactivated postbiotic targeting the gut-joint axis, designed for mobility and joint health support; won Gold Medal and Grand Prize at the 2025 Japan Tokyo Innovation Genius International Invention Exhibition and Gold at the 2025 Seoul International Invention Fair.
• ABKefir® Seven-strain symbiotic fermentation formula using proprietary SYNTEK technology, derived from a kefir fermentation concept; supports digestive comfort and gut microbiome balance, rich in organic acids and polysaccharides.
• BY2 Functional probiotic (Lactobacillus paracasei) with bile salt tolerance and cholesterol adsorption capabilities, supporting blood lipid balance and cardiovascular/metabolic nutrition.
• M1 Postbiotic Heat-killed Lactobacillus kefiranofaciens M1 postbiotic sourced from Mongolian kefir, targeting respiratory health; won the 2022 Taiwan Lactic Acid Bacteria Association Innovation Product Award.
• SYNPET® Pet health probiotic series including SYNPET TRENAL for kidney health in cats and dogs, with bone strength and immune modulation benefits; Taiwan's first pet probiotic with canine/feline clinical trial validation.
• CDMO / OEM / ODM Probiotic Manufacturing Services Contract development and manufacturing organization providing customized probiotic formulations, blending, and packaging services for brand partners; covers full product lifecycle from strain selection and clinical validation to customized formulations and smart packaging as a one-stop service.

Quantifiable outcome

• TWK10 clinical trial: up to 48% NK cell cytotoxic activity increase in adults 50-75 years
• +5 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Lonza Group (Switzerland)coreChannel Partner/ Reseller/ DistributorIn September 2020, Synbiotech signed an exclusive distribution agreement with Lonza Group for TWK10 probiotic ingredients in the US, Canada, Europe, and Brazil markets. Lonza, a leading global CDMO in pharmaceutical and biotech, promotes TWK10 for sports nutrition and active lifestyle applications. The partnership includes joint development and optimization of TWK10 for new markets and applications. This is a flagship global partnership that significantly expanded Synbiotech's international reach.
• Cosmax NBT Inc. (Korea)coreStrategic or Co-development PartnerIn January 2023, Synbiotech signed an exclusive distribution and R&D collaboration agreement with Cosmax NBT (Cosmax NBT Inc., Korea Stock Exchange: 222040) for TWK10 in Korea. Cosmax NBT, Korea's largest health functional food ODM company, has launched TWK10-containing products in Korea. In 2024, the partnership was expanded to include joint research on TWK10's efficacy for metabolic syndrome. The collaboration includes clinical trials and marketing strategy development for the Korean market.
• Fu Jen Catholic University (Taiwan)coreStrategic or Co-development PartnerTWK10 probiotic strain was technology-transferred from Fu Jen Catholic University Professor Tsai Zong-you (蔡宗佑), and further developed in collaboration with National Taiwan Sport University. This academic-industry collaboration produced the world's first sports probiotic strain, which is the cornerstone product of Synbiotech's global business.
• National Taiwan Sport University (Taiwan)coreStrategic or Co-development PartnerJoint research with National Taiwan Sport University produced the foundational clinical evidence for TWK10's sports performance and muscle health applications. Animal and human clinical trials demonstrating TWK10's effects on muscle mass, endurance, fatigue reduction, and exercise recovery were conducted in collaboration with the university.
• National Taiwan University (Taiwan)minorStrategic or Co-development PartnerTechnology transfer from National Taiwan University for the M1 postbiotic strain (Lactobacillus kefiranofaciens M1), sourced from traditional Mongolian kefir. M1 is the company's first postbiotic product, targeting respiratory health applications.
• Malaysia University of Technology (Universiti Malaysia Perlis)minorStrategic or Co-development PartnerClinical trial collaboration for SynForU-HerCare targeting vaginal health in pregnant women. Joint research conducted with Malaysian university validated the probiotic's effects on vaginal and gut microbiota in pregnant women.
• National Chung Hsing University (Taiwan)minorStrategic or Co-development PartnerPartnership with National Chung Hsing University's Global Change Biology Research Center in the Syn-Bio-Diversity Initiative, contributing microbiome research expertise for endangered species conservation (雷公蛙/Mekong butterfly frog).
• Wiley (John Wiley & Sons)minorOthersTWK10 research paper published in Physiological Reports was recognized by Wiley as a 'Top Cited Article' in 2023. This academic recognition validates the scientific quality and impact of Synbiotech's research outputs.

Scale indicators8 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Novonesis (formerly Chr. Hansen): Novonesis is the world's largest probiotic ingredient supplier with a broad strain portfolio spanning human nutrition, animal health, and plant biosolutions. As Synbiotech's largest functional competitor, it sets the benchmark for scale, regulatory reach, and clinical depth in the human nutraceutical and animal feed probiotic markets.
• Lallemand Health Solutions: Lallemand is a Canadian-headquartered global supplier of probiotic and yeast-based ingredients for human nutrition with deep R&D and CDMO capabilities. It competes head-to-head with Synbiotech for tier-1 supplement and functional-food accounts in North America, Europe, and Asia.
• ADM (Biopolis/Bioiberica probiotic unit): ADM is a global nutrition giant that supplies probiotics, postbiotics, and other functional ingredients through acquired units. Its scale and existing CPG relationships make it a credible competitor for Synbiotech's TWK10 ingredient business with global sports nutrition and healthy aging brands.
• Kerry Group (GanedenBC30): Kerry is a global taste and nutrition company that markets GanedenBC30 probiotic ingredient to food, beverage, and supplement brands. It overlaps with Synbiotech in functional food and beverage application, especially in the US and Europe where Symbiotech routes TWK10.
• Lesaffre (Gnosis by Lesaffre): Lesaffre is a global yeast and fermentation specialist whose Gnosis division supplies probiotic and postbiotic ingredients, leveraging fermentation expertise analogous to Synbiotech's SYNTEK thorough platform. It overlaps in CDMO/B2B ingredient supply and competes for sports nutrition and healthy aging accounts globally.

Direct peers

• BioGaia: BioGaia is a Sweden-based probiotic company that develops and markets clinically validated Lactobacillus reuteri strains for human and animal health, sold as both branded finished products and licensed ingredients. It is directly comparable to Synbiotech on clinical-substantiation strategy, gut-axis strain targeting, and B2B ingredient licensing.
• Probi AB (Symrise-owned): Probi is a Swedish probiotic ingredient specialist now owned by flavor & nutrition giant Symrise. It sells clinically validated probiotic strains to global supplement brands, making it one of the most direct mid-tier comparables to Synbiotech's B2B probiotic model and channel strategy.
• AB Biotics (AB-Biotics): AB Biotics is a Spanish probiotic company developing proprietary, clinically tested bacterial strains for human and animal health, sold as ingredients to brands and as finished supplements in Iberia. Comparable to Synbiotech in company size, proprietary-strain strategy, and CDMO/finished-product mix.
• Yakult Honsha: Yakult is a global probiotic beverage and ingredient company built on Lactobacillus casei strain Shirota. While its primary market is finished fermented dairy drinks, it competes with Synbiotech for probiotic health claims, clinical credibility, and consumer mindshare in Asia and other global markets.

Regional players

• Morinaga Milk Industry: Morinaga is a Japanese dairy and probiotic company with clinically validated Bifidobacterium and Lactobacillus strains for gut, infant, and immune health. It is directly relevant as a peer targeting the same Japanese and APAC healthy-aging consumer that Synbiotech addresses via TWK10.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/synbiotechinc
• YouTubeyoutube.com/user/SynbioTech
• Facebookfacebook.com/synbiotech.tw
• LinkedIntw.linkedin.com/in/synbiotech
• Instagraminstagram.com/synbio_tech?utm_medium=copy_link

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synbiotech